Multiple Myeloma Coverage from Every Angle

EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma

By: Julia Fiederlein
Posted: Thursday, June 17, 2021

The cereblon E3 ligase modulator compound iberdomide plus dexamethasone in combination with daratumumab, bortezomib, or carfilzomib showed activity in some heavily pretreated patients with relapsed or refractory multiple myeloma, according to Sagar Lonial, MD, of Emory University, Atlanta, and colleagues. Findings from the ongoing phase I/II CC-220-MM-001 trial presented during the European Hematology Association Virtual Congress (EHA2021; Abstract S187) also revealed a manageable safety profile.

As of December 14, 2020, a total of 34, 24, and 7 patients were administered dexamethasone plus escalating oral doses of iberdomide in combination with either daratumumab, bortezomib, or carfilzomib, respectively. Iberdomide doses ranged from 1.0 to 1.6 mg.

The most frequently reported hematologic grade 3 or 4 treatment-emergent adverse events were neutropenia (63%), anemia (28%), leukopenia (28%), and lymphopenia (25%) with daratumumab; neutropenia (29%) and thrombocytopenia (25%) with bortezomib; and lymphopenia (57%) and neutropenia (43%) with carfilzomib. Grade 4 neutropenic sepsis was reported in one patient treated with 1.2 mg of the daratumumab regimen. According to the study authors, the incidence rates of grade 3 or 4 nonhematologic treatment-emergent adverse events were low in all cohorts.

The objective response rate was 41% with daratumumab; the clinical benefit rate was 52%, and the disease control rate was 86%. In patients treated with bortezomib, the objective response rate was 58%; the clinical benefit and disease control rates were 67% and 92%, respectively. Of note, responses to the daratumumab and bortezomib regimens were reported in patients whose disease was refractory to prior therapy with these agents. An objective response rate of 57% was observed with carfilzomib; the clinical benefit rate was 57%, and the disease control rate was 86%. The median duration of response was 63.3 weeks with bortezomib and not reached with daratumumab and carfilzomib. The recommended phase II dose of the daratumumab regimen was 1.6 mg; dose evaluation continues in the bortezomib and carfilzomib cohorts.

Disclosure: For disclosures of study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.